Elastin-Like Polypeptide Delivery System Placental Transfer Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery methods during pregnancy face challenges due to the uncertainty of therapeutic agents crossing the placental barrier, leading to potential adverse effects on the fetus, and the lack of clinical data on drug effects in pregnant women, which hinders drug development and use for pregnancy-related conditions.
Innovation Solution
The use of elastin-like polypeptides (ELPs) specifically designed to target the placenta, with varying molecular weights and sequences, to deliver therapeutic agents while minimizing their passage across the placenta, thereby protecting the fetus and allowing for effective treatment of pregnancy-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic agents are administered to pregnant mothers, then the treatment efficacy for pregnancy-related conditions is improved, but the risk of adverse effects on the developing fetus increases
Solution Approach 1:
The patent uses an elastin-like polypeptide (ELP) carrier as an intermediary to deliver therapeutic agents to the placenta. The ELP carrier binds to the therapeutic agent and facilitates its transport across the placental barrier through active transport mechanisms, while the therapeutic agent itself does not directly cross the barrier. This mediator approach allows treatment of pregnancy-related conditions while protecting the fetus from direct exposure to potentially harmful therapeutic agents.
Solution Approach 2:
The patent employs parameter changes by modifying the molecular weight of the ELP carrier (ranging from 10-100 kDa) to optimize placental transfer efficiency. By adjusting this physical parameter, the carrier can be tuned to cross the placental barrier effectively while maintaining the ability to protect the therapeutic agent, thus resolving the contradiction between treatment efficacy and fetal safety.
2Reliability
If large molecular weight drug carriers are used for placental transfer, then the ability to prevent passive crossing is improved, but the results become highly variable depending on hydrophobicity and charge
Solution Approach 1:
The patent systematically varies the molecular weight parameter of the ELP carrier (10-100 kDa) to optimize placental transfer. This parameter change allows the carrier to be large enough to prevent passive diffusion of therapeutic agents while maintaining sufficient flexibility and appropriate surface properties for active transport mechanisms, thereby achieving consistent and reliable placental transfer across different therapeutic agents.
Solution Approach 2:
The ELP carrier functions as a composite material combining elastin-like structural properties with tailored molecular weight characteristics. This composite approach integrates the benefits of large molecular weight (preventing passive crossing) with optimized physical-chemical properties (hydrophobicity and charge) to achieve consistent active transport across the placental barrier.
3Object-affected harmful factors
If molecular weight of ELP is increased to prevent therapeutic agent crossing, then fetal protection is improved, but the accumulation in placental regions may be reduced
Solution Approach 1:
The patent identifies an optimal molecular weight range (10-100 kDa) for ELP carriers that balances two competing requirements: sufficient size to prevent therapeutic agent leakage and optimize fetal protection, while maintaining adequate placental accumulation through active transport mechanisms. This parameter optimization resolves the contradiction by finding the sweet spot where both fetal protection and placental delivery efficacy are maximized.
Data Source
AI summary
A composition including an elastin-like polypeptide (ELP) coupled to a therapeutic agent is provided. The ELP comprises at least about 5 repeats of the amino acid sequence VPGXG. Further provided is a method of using the composition for therapeutic agent delivery during pregnancy to reduce the amount of the therapeutic agent crossing a placenta in a pregnant subject. The method includes administering to the pregnant subject an effective amount of the composition comprising the ELP coupled to the therapeutic agent.